Manufacturing Expansion

RNS Number:8805H
Provalis PLC
2 August 2001


FOR IMMEDIATE RELEASE                                             2 AUGUST 2001



PROVALIS PLC



    Second Facility in Deeside to support growing supply and distribution
              operations in Healthcare and Diagnostics divisions



Provalis plc (LSE.PRO; NASDAQ.PVLS), the UK based integrated healthcare
company, has entered into a 10 year lease for a new building near to its
existing head office and manufacturing facility in Deeside, North Wales.
Provalis is having the new building extended to 11,000sq.ft, and converted to
provide expanded warehouse facilities, and a dedicated diagnostics
manufacturing suite.



The warehouse facilities are due for completion by September 2001, and will be
used by both the Healthcare and Diagnostic divisions.  The expanding
Healthcare division is particularly in need of this additional space following
the recent, successful launch of Pennsaid(R) into the UK market.



The manufacturing suite, which will be the largest section in the new
building, will accommodate a new automated filling and assembly line for the
cartridges of the Company's diabetes test, GlycosalTM. It is expected to come
on stream in stages from early 2002. This additional manufacturing capacity is
required to meet the anticipated uptake and growth in market demand for
GlycosalTM, which was launched in mid 2000. The manufacturing suite will also
house the pilot plant for Provalis' new diabetes diagnostic product codenamed
'G5'.



Phil Gould, Chief Executive of Provalis commented: "The expansion of our
Operating businesses, Healthcare and Diagnostics, is critical to rapidly
delivering the Provalis' stated strategy of generating positive cash flows to
support the Group's longer term and high value R&D programmes. This investment
in new manufacturing and warehouse facilities provides us with a stronger
product supply and distribution base for these key divisions for the future"



END



Provalis' Internet Website ; http://www.provalis.com



"Safe Harbor" Statement under the US Private Securities Litigation Reform Act
of 1995:  Some or all of the statements in this document that relate to future
plans, expectations, events, performances and the like are forward looking
statements as defined in the US Private Securities Litigation Reform Act of
1995.  Actual results of events could differ materially from those described
in the forward looking statements due to a variety of factors, including those
set forth in Provalis plc's filings with the US Securities and Exchange
Commission.



For further information:-


Dr Phil Gould, Provalis plc,                                 Tel:  01244 833463


Mr Lee Greenbury, Provalis plc,                              Tel:  01244 833402


Lisa Baderoon, Buchanan Communications,                     Tel:  020 7466 5000

                                                         (Mobile: 07721 413496)



Notes to Editors



Provalis plc (LSE.PRO and NASDAQ.PVLS) is an integrated healthcare business
with three separate divisions focused on the supply and sale of prescription
medicines, the development, manufacture and sale of medical diagnostics
worldwide, and the development of new therapeutic products, such as vaccines
to combat infectious diseases.



The three divisions are:-



Healthcare - This division sells and markets branded, third party,
prescription medicines in the UK to GPs and hospitals through its own
regionally managed sales force.  This division sells products in the areas of
gastroenterology, osteoarthritis, osteoporosis, migraine and dermatology.



Medical Diagnostics - This division develops and sells medical diagnostic
products to world markets through distributors.  The division has an
established business in diagnostic products, including the innovative products
GlycosalTM and OsteosalTM in the areas of diabetes and osteoporosis
respectively.



Therapeutic R&D - This division develops a range of recombinant surface
protein based antigen vaccines for serious infectious diseases.  It has a
number of candidate vaccines at the pre-clinical stage of development.
Globaldata (LSE:DATA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024